Is there a «window of therapeutic opportunity» for testosterone replacement therapy for age-related hypogonadism in men?


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses the issues of cardiovascular safety of testosterone replacement therapy (TRT) in age-related androgen deficiency in men. TRT may exacerbate cardiovascular disease in some patients with suboptimal testosterone levels. In general, the risk of CVD with TRT is low. There are individual differences in the timing of the onset of age-related androgen deficiency in men, mainly due to the sexual constitution. Accordingly, the rate of progression of atherosclerosis will vary in different men of the same age, depending on the severity of testosterone deficiency and genetic factors. At the same time, the greatest risks, according to the data available to date, were noted in men over 60-65 years of age.

Full Text

Restricted Access

About the authors

S. S Apetov

Endocrine Health Center

Email: apetov@rambler.ru
Chelyabinsk, Russia

V. V Apetova

Endocrine Health Center

Chelyabinsk, Russia

References

  1. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-doi: 10.1056/NEJMoa1000485.
  2. Vigen R., O'Donnell C.I., Baron A.E., et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-doi: 10.1001/jama.2013.280386. Erratum in: JAMA. 2014 Mar 5;311(9):967.
  3. Finkle W.D., Greenland S., Ridgeway G.K., et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi: 10.1371/journal.pone.0085805.
  4. Baillargeon J., Kuo Y.F., Westra J.R., et al. Testosterone Prescribing in the United States, 2002-2016. JAMA. 2018;320(2):2002. doi: 10.1001/jama.
  5. Cheetham T.C., An J., Jacobsen S.J., et al. Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency. JAMA.Intern Med. 2017;177(4):491-99. Doi: 10.1001/ jamainternmed.22018.7999.
  6. Shores M.M. Testosterone treatment and cardiovascular events in prescription database studies. Asian J Androl. 2018;20(2):138-44. doi: 10.4103/aja.aja_25_17.
  7. Pantalone K.M., George J., Ji X., et al. Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality. Basic Clin Androl. 2019;29:5. doi: 10.1186/s12610-019-0085-7.
  8. Shores M.M., Smith N.L., Forsberg C.W., et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-58. doi: 10.1210/jc.2011-2591.
  9. Loo S.Y., Azoulay L., Nie R., et al. Cardiovascular and Cerebrovascular Safety of Testosterone Replacement Therapy Among Aging Men with Low Testosterone Levels: A Cohort Study. Am J Med. 2019;132(9): 1069-77.e4. Doi: 10.1016/j. amjmed.2(019.03.022.
  10. Beral V., Gaitskell K., et al. Collaborative Group On Epidemiological Studies Of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta analysis of 52 epidemiological studies. Lancet. 2015;385(9980):1835-42. Doi: 10.1016/ S0140-6736(14)61687-1.
  11. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. doi: 10.1001/jama.288.3.321.
  12. Rossouw J.E, Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297(13):1465-77. doi: 10.1001/jama.297.13.1465. Erratum in: JAMA. 2008;299(12):1426.
  13. Manson J.E, Aragaki A.K., Rossouw J.E., et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-38. Doi: 10.1001/ jama.2017.11217.
  14. Barrett-Connor E. Hormones and heart disease in women: the timing hypothesis. Am. J. Epidemiol. 2007;166(5):506-10. doi: 10.1093/aje/ kwm214.
  15. Hodis H.N., Collins P., Mack W.J., et al. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric. 2012;15(3):217-28. doi: 10.3109/13697137.2012.656401.
  16. ESHRE Capri Workshop Group. Hormones and cardiovascular health in women. Hum Reprod Update. 2006;12(5):483-97. Doi: 10.1093/ humupd/dml028.
  17. Gao Z, Chen Z., Sun A., et al. Gender differences in cardiovascular disease. Med Nov Tech Dev. 2019;(4):100025.
  18. Kapoor D, Jones T.H. Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention? Drugs Aging. 2008;25:357-69.
  19. Kupelian V, Hayes F.J., Link C.L., et al. Inverse association of testosterone and the metabolic syndrome in men is consistent across race and ethnic groups. J Clin Endocrinol Metab. 2008;93(9):3403-10. doi: 10.1210/jc.2008- 0054.
  20. Hackett G. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. Sex Med Rev. 2019;7(3):476-90. doi: 10.1016/j.sxmr.2018.12.004.
  21. Jones T.H. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496-503. Doi: 10.1016/j. tem.2010.03.002.
  22. Webb C.M., Collins P Role of Testosterone in the Treatment of Cardiovascular Disease. Eur Cardiol. 2017;12(2):83-7. Doi: 10.15420/ ecr.2017:21:1.
  23. Khaw K.T., Dowsett M., Folkerd E., et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694-701. doi: 10.1161/CIRCULATI0NAHA.107.719005.
  24. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93(1):68-75. doi: 10.1210/jc.2007-1792.
  25. Akishita M., Hashimoto M., Ohike Y, et al. Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis. 2010;210(1):232-36. doi: 10.1016/j.atherosclerosis.2009.10.037.
  26. Holmegard H.N., Nordestgaard B.G., Jensen G.B., et al. Sex Hormones and Ischemic Stroke: A Prospective Cohort Study and Meta-Analyses. J Clin Endocrinol Metab. 2016;101(1):69-78. doi: 10.1210/jc.2015-2687.
  27. Corona G., Rastrelli G., Di Pasquale G., et al. Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. J Sex Med. 2018;15(9):1260-71. Doi: 10.1016/j. jsxm.2018.06.012.
  28. Shores M.M., Biggs M.L., Arnold A.M., et al. Testosterone, dihydrotestosterone, and incident cardiovascular disease and mortality in the cardiovascular health study. J Clin Endocrinol Metab. 2014;99(6):2061-68. Doi: 10.1210/ jc.2013-3576.
  29. Haring R., Teng Z., Xanthakis V., et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study. Clin Endocrinol. (Oxf). 2013;78(4):629-34. doi: 10.1111/cen.12013.
  30. Collet T.H., Ewing S.K., Ensrud K.E., et al. Endogenous Testosterone Levels and the Risk of Incident Cardiovascular Events in Elderly Men: The MrOS Prospective Study. J Endocr Soc. 2020;4(5):bvaa038. doi: 10.1210/jendso/ bvaa038.
  31. Luo S., Yeung Sh.L.A., Zhao J.V., et al. Association of genetically predicted testosterone with thromboembolism, heart failure, and myocardial infarction: mendelian randomisation study in UK Biobank. BMJ. 2019;364:1476. Doi: 10.1136/ bmj.l476.
  32. Holmegard H.N., Nordestgaard B.G., Schnohr P., et al. Endogenous sex hormones and risk of venous thromboembolism in women and men. J Thromb Haemost. 2014;12(3):297-305. doi: 10.1111/jth.12484.
  33. Roetker N.S., MacLehose R.F., Hoogeveen R.C., et al. Prospective Study of Endogenous Hormones and Incidence of Venous Thromboembolism: The Atherosclerosis Risk in Communities Study. Thromb Haemost. 2018;118(11):1940-50. doi: 10.1055/s-0038-1673613.
  34. Soisson V., Brailly-Tabard S., Helmer C., et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75(3):282-8. Doi: 10.1016/j. maturitas.2013.04.012.
  35. Yeap B.B. Testosterone and its metabolites: differential associations with cardiovascular and cerebrovascular events in men. Asian J Androl. 2018;20(2):109-14. doi: 10.4103/aja. aja_50_17.
  36. Yeap B.B., Alfonso H., Chubb S.A., et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99(1):E9-18. doi: 10.1210/jc.2013-3272.
  37. Wallis C.J., Lo K., Lee Y., et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet. Diab Endocrinol. 2016;4(6):498-506. Doi: 10.1016/ S2213-8587(16)00112-1.
  38. Hackett G.I., Ramachandran S., Strange R., et al. Statin, testosterone and PDE5Is and age-related mortality in type 2 diabetes. World J Diab. 2017;8:104-11. doi: 10.4239/wjd.v8.i3.104.
  39. Hackett G., Heald A.H., Sinclair A., et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins.Int J Clin Pract. 2016;70:244-53. doi: 10.1111/ijcp.12779.
  40. Baillargeon J., Urban R.J., Kuo Y.F., et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother. 2014;48(9):1138-44. doi: 10.1177/1060028014539918.
  41. Saad F., Yassin A., Haider A., et al. Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men. Korean J Urol. 2015;56(4):310-doi: 10.4111/kju.2015.56.4.310.
  42. Snyder P.J., Bhasin S., Cunningham G.R., et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-24. doi: 10.1056/NEJMoa1506119.
  43. Alexander G.C., Iyer G., Lucas E., et al. Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and MetaAnalysis. Am J Med. 2017;130(3):293-305. doi: 10.1016/j.amjmed.2016.09.017.
  44. Qeseem A., Horwitch C.A., Vijan S., et al. Testosterone treatment in adult men with age-related low testosterone: a clinical guideline from the American College of Physicians. Ann Intern Med. 2020;172:126-33. doi: 10.7326/M19-0882.
  45. Baillargeon J., Urban R.J., Morgentaler A., et al. Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. Mayo Clin Proc. 2015;90:1038-45. Doi: 10.1016/j. mayocp.o0l5.05.012.
  46. Sharma R., Oni O.A., Chen G., et al. Association Between Testosterone Replacement Therapy and the Incidence of DVT and Pulmonary Embolism: A Retrospective Cohort Study of the Veterans Administration Database. Chest. 2016;150(3):563-71. Doi: 10.1016/j. chest.2016.05.007.
  47. Li H, Benoit K., Wang W, et al. Association between Use of Exogenous Testosterone Therapy and Risk of Venous Thrombotic Events among Exogenous Testosterone Treated and Untreated Men with Hypogonadism. J Urol. 2016;195(4 Pt.:1065- 72. doi: 10.1016/j.juro.2015.10.134.
  48. Martinez C., Suissa S., Rietbrock S., et al. Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ. 2016;355:i5968. Doi: 10.1136/ bmj.i5968.
  49. Walker R.F, Zakai N.A., MacLehose R.F, et al. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. JAMA.Intern Med. 2020;180(2):190-97. Doi: 10.1001/ ]amaioternmed.0Q1-.535.
  50. Otsuke F, Yesude S., Noguchi T, et al. Pathology of coronary atherosclerosis and thrombosis. Cardiovasc Diagn Ther. 2016;6(4):396-408. doi: 10.21037/cdt.2016.06.01.
  51. Budoff M.J., Ellenberg S.S., Lewis C.E., et al. Testosterone Treatment and Coronary Artery Plaque Volume in Older Men With Low Testosterone. JAMA. 2017;317(7):708-16. doi: 10.1001/jama.2016.21043.
  52. Beserie S, Harman S.M., Trevison T.G., et al. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial. JAMA. 2015;314(6):570-81. Doi: 10.1001/ jama.2015.8881.
  53. Drinke P.J, Jochen A.L., Cuisinier M., et al. Polycythemia as a complication of testosterone replacement therapy in nursing home men with low testosterone levels. J Am Geriatr Soc. 1995;43:899-901. doi: 10.1111/j.1532-5415.1995.tb05534.x.
  54. Chehle E.J., Hayek M.E., Morley J.E. Testosterone replacement therapy and cardiovascular risk factors modification. Aging Male. 2011;14(2):83-90. doi: 10.3109/13685538.2010.541538.
  55. Vermeulen A., Kaufman J.M., Goemeere S., et al. Estradiol in elderly men. Aging Male. 2002;5(2):98-102.
  56. Clelend W.H., Mendelson C.R., Simpson E.R. Aromatase activity of membrane fractions of human adipose tissue stromal cells and adipocytes. Endocrinol. 1983;113(6):2155-60.
  57. Schneider G., Kirschner M.A., Berkowitz R., et al. Increased estrogen production in obese men. J Clin Endocrinol Metab. 1979;48(4):633-38. doi: 10.1210/jcem-48-4-633.
  58. Swerdloff R.S., Wang C., Cunningham G., et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonedel men. JClin. Endocrinol Metab. 2000;85(12):4500-10. doi: 10.1210/jcem.85.12.7045.
  59. Bang A.K., Jergensen N., Rejpert-De Meyts E, et al. UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecenoete. A Retrospective Experience from 207 Men with Hypogonadism. Front. Endocrinol. (Lausanne). 2013;4:94. doi: 10.3389/fendo.2013.00094.
  60. Wrenicz J.K., Cygenkiewicz I., Rosiek M., et al. The relationship between sex hormones and lipid profile in men with coronary artery disease.Int J Cardiol. 2005;101(1):105-10. Doi: 10.1016/j. ijcard.2004.07.010.
  61. Tivesten A., Hulthe J., Wallenfeldt K., et al. Circulating Estradiol Is an Independent Predictor of Progression of Carotid Artery Intima-Media Thickness in Middle-Aged Men. J Clin Endocrinol Metab. 2006;91:4433-7. Doi: 10.1210/ jc.2006-0932.
  62. Abbott R.D., Leuner L.J., Rodriguez B.L., et al. Serum estradiol and risk of stroke in elderly men. Neurol. 2007;68(8):563-68. doi: 10.1212/01. wnl.00002544 73.88647.ca.
  63. Tripethi Y., Hegde M. Serum estradiol and testosterone levels following acute myocardial infarction in men. Ind J Physiol Pharmacol. 1998;49:291-94.
  64. Mohamad M.J., Mohammad M.A., Kareyyem M., et al. Serum levels of sex hormones in men with acute myocardial infarction. Neur Endocrinol Lett. 2005;28{2):122585.
  65. Aperne R.R., Rejesweri D.R., Remelingem K., et al. Estradiol and lipid levels in men with acute myocardial infarction.Int J Res Med Sci. 2020;8:989-92.
  66. Lekshmen K.M., Kaplan B., Trevison T.G., et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010;95(8):3955-69. doi: 10.1210/jc.2010-0102.
  67. Amory J.K., Watts N.B., Easley K.A., et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2009;89(2):503-10. doi: 10.1210/jc.2003-031110.
  68. Schubert M, Minnemenn T., Hubler D., et al.Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab. -009;84(11):59-4-39. Doi: 10.1210/ jc.2009-0897.
  69. Jenkowske E.A., Rozentryt P., Ponikowske B, et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009;301(18):1892-901. Doi: 10.1001/ jama1.2009.639.
  70. Renoux C., DellAniello S., Brenner B, et al. Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism. Pharmacoepidemiol. Drug Saf. -017;-6(5):559-60. Doi: 10.1002/ pds.4197.
  71. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;396(8990):1575-82.
  72. Spitzer W.O. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation. J. Obstet. Gynaecol. Can. 2003;25(12):1011-doi: 10.1016/s1701-2163(16)30392-5.
  73. Dinger J.C., Heinemann L.A., Kuhl-Hebich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 192,975 women-yeers of observation. Contraception. 2007;75(5):399-59. doi: 10.1016/a.oontreoeption.2006.12.019.
  74. van Hylckeme Vlieg A., Helmerhorst F.M., Vendenbroucke J.P, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA cese-control study. BMJ. 2009;339:b2921. doi: 10.1136/bmj.b2921
  75. Bloemenkemp K.W., Rosendeel F.R., Helmerhorst F.M., et al. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med. 2000;160(1):99-52. Doi: 10.1001/ archinte.160.1.49.
  76. Glueck C.J., Goldenberg N., Wang P. Thromboembolism peaking 3 months after starting testosterone therapy: testosterone-thrombophilia interactions. J Investig Med. ;66(4):733-38. doi: 10.1136/jim-2017-000637.
  77. Sandset P.M, H0ibraaten E., Eilertsen A.L., et al. Mechanisms of thrombosis related to hormone therapy. Thromb Res. 2009;123(Suppl. :S70-73. doi: 10.1016/S0049-3848(09) 70015-5.
  78. Costello B.T, Sprung K., Coulter S.A. The Rise and Fall of Estrogen Therapy: Is Testosterone for «Manopause» Next? Tex Heart Inst J. 2017;44(5):338-40. doi: 10.14503/THIJ-17-6360.
  79. Shoskes J.J., Wilson M.K., Spinner M.L. Pharmacology of testosterone replacement therapy preparations. Transl Androl Urol. 2016;5(6):834-43. doi: 10.21037/tau.2016.07.10.
  80. Layton J.B., Meier C.R., Sharpless J.L., et al.Comparative Safety of Testosterone Dosage Forms. JAMA.Intern Med. 2015;175(7):1187-96. doi: 10.1001/jamainternmed.2015.1573. Erratum in: JAMA Intern Med. 2015;175(7):1248.
  81. Borst S.E., Yarrow J.F. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. Am J Physiol Endocrinol Metab. 2015;308(12):E1035-42. Doi: 0.1152/ ajpendo.001 11.2015.
  82. Sharma R., Oni O.A., Gupta K., et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706-15. doi: 10.1093/eurheartj/ehv346.
  83. Oni O.A., Dehkordi S.H.H., Jazayeri M.A., et al. Relation of Testosterone Normalization to Mortality and Myocardial Infarction in Men With Previous Myocardial Infarction. Am J Cardiol. 2019;124(8):1171-78. Doi: 10.1016/j. amjcard.2019.07.019.
  84. Mulhall J.P., Trost L.W., Brannigan R.E., et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-32. Doi: 10.1016/j. juro.2018.03.115.
  85. Bhasin S., Cunningham G.R., Hayes F.J., et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-59. Doi: 10.1210/ jc.2009-2354.
  86. Khera M., Broderick G.A., Carson C.C., et al. Adult-Onset Hypogonadism. Mayo Clin Proc. 2016;91(7):908-26. doi: 10.1016/j. mayocp.20016.04.022.
  87. Stepaniak U., Szafraniec K., Kubinova R., et al. Age at natural menopause in three central and eastern European urban populations: the HAPIEE study Maturitas. 2013;75(1):87-93. Doi: 10.1016/j. maturitas.2013.02.008.
  88. Bhasin S., Brito J.P., Cunningham G.R., et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-44. doi: 10.1210/jc.2018-00229.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2022 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies